scholarly journals Combined multimodal ctDNA analysis and radiological imaging for tumor surveillance in Non-small cell lung cancer

2022 ◽  
Vol 15 (1) ◽  
pp. 101279
Author(s):  
Martin Metzenmacher ◽  
Balazs Hegedüs ◽  
Jan Forster ◽  
Alexander Schramm ◽  
Peter A. Horn ◽  
...  
Cancers ◽  
2020 ◽  
Vol 12 (11) ◽  
pp. 3112
Author(s):  
Elisa Gobbini ◽  
Aurélie Swalduz ◽  
Matteo Giaj Levra ◽  
Sandra Ortiz-Cuaran ◽  
Anne-Claire Toffart ◽  
...  

Tumor genomic profiling has a dramatic impact on the selection of targeted treatment and for the identification of resistance mechanisms at the time of progression. Solid tissue biopsies are sometimes challenging, and liquid biopsies are used as a non-invasive alternative when tissue is limiting. The clinical relevance of tumor genotyping through analysis of ctDNA is now widely recognized at all steps of the clinical evaluation process in metastatic non-small cell lung cancer (NSCLC) patients. ctDNA analysis through liquid biopsy has recently gained increasing attention as well in the management of early and locally advanced, not oncogene-addicted, NSCLC. Its potential applications in early disease detection and the response evaluation to radical treatments are promising. The aim of this review is to summarize the landscape of liquid biopsies in clinical practice and also to provide an overview of the potential perspectives of development focusing on early detection and screening, the assessment of minimal residual disease, and its potential role in predicting response to immunotherapy. In addition to available studies demonstrating the clinical relevance of liquid biopsies, there is a need for standardization and well-designed clinical trials to demonstrate its clinical utility.


2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 8577-8577
Author(s):  
John F. Palma ◽  
Corinna Woestmann ◽  
Sylvie McNamara ◽  
Bernd Hinzmann ◽  
Sebastian Fröhler ◽  
...  

2020 ◽  
Author(s):  
John Jiang ◽  
Christine Ju ◽  
Corinna Woestmann ◽  
Aarthi Balasubramanyam ◽  
Liu Xi ◽  
...  

2017 ◽  
Vol 12 (7) ◽  
pp. 1061-1070 ◽  
Author(s):  
Suzanne Jenkins ◽  
James C-H. Yang ◽  
Suresh S. Ramalingam ◽  
Karen Yu ◽  
Sabina Patel ◽  
...  

Author(s):  
Maria Jacob ◽  
Vanessa Santos ◽  
Adriana Magalhães ◽  
António Morais ◽  
Henrique Queiroga ◽  
...  

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 2547-2547
Author(s):  
Everett J Moding ◽  
Yufei Liu ◽  
Barzin Nabet ◽  
Jacob J. Chabon ◽  
Aadel Chaudhuri ◽  
...  

2547 Background: Detection of molecular residual disease via circulating tumor DNA (ctDNA) analysis after chemoradiation (CRT) in localized non-small cell lung cancer (NSCLC) predicts risk of relapse. We explored the hypotheses that (1) patients with undetectable ctDNA after CRT may not require consolidation immunotherapy (CI) and (2) ctDNA analysis could monitor the effectiveness of CI in patients with residual ctDNA after CRT. Methods: We applied CAPP-Seq ctDNA analysis to 88 plasma and matched leukocyte samples collected pre-CRT, post-CRT but pre-CI, and mid-CI in 22 patients with Stage IIB-IIIB NSCLC treated with CRT followed by CI. Identification of patient-specific tumor variants was performed using tumor tissue or pretreatment plasma, and ctDNA was quantified using a tumor mutation-informed bioinformatic strategy. Freedom from progression (FFP) defined radiographically by RECIST 1.1 criteria was compared in patients with ctDNA detected or not detected at pre-CI and mid-CI landmarks. Results: Median follow up from the start of CRT was 11 months. ctDNA detection was associated with inferior rates of FFP when compared to patients with ctDNA not detected both pre-CI (12-month 33% vs. 76%, P = 0.015, HR 7.51, 95% CI 1.47-38.24) and mid-CI (12-month 0% vs. 86%, P < 0.0001, HR 123.3, 95% CI 16.21-937.8). In patients with undetectable ctDNA after CRT, FFP was similar to a historical cohort of patients with undetectable ctDNA after CRT alone (12-month 88% vs. 87%, P = 0.56, HR 0.55, 95% CI 0.07-4.18), suggesting that such patients may not benefit from CI. All patients with detectable ctDNA pre-CI in whom ctDNA increased mid-CI developed progressive disease. Finally, in 2 patients with ctDNA detected after CRT, CI led to elimination of ctDNA at the mid-CI timepoint. One of these patients developed an isolated local recurrence 22 months after CRT and the other patient is currently disease free at 11 months, suggesting clinical benefit from CI. Conclusions: Our results suggest that ctDNA analysis may allow personalization and response monitoring of CI following CRT for NSCLC. Validation in more patients followed by prospective testing in clinical trials will be required to establish clinical utility of such an approach.


Sign in / Sign up

Export Citation Format

Share Document